Drug Trial Radar · NCT01885078
An Extension Study in Participants With Moderate to Severe Rheumatoid Arthritis
Last checked: Nov 20, 2026Latest source record: Apr 25, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,877
Actual
Start
Jun 27, 2013
Primary completion
Nov 12, 2020
Study completion Nov 12, 2020
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- First posted
- Jun 24, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to investigate the long-term safety and any side effects of baricitinib in participants who have completed a previous baricitinib rheumatoid arthritis study. The study provides 7 years of additional treatment with baricitinib.
Conditions
- Rheumatoid Arthritis
Interventions
BaricitinibDrug
Administered orally
PlaceboDrug
Administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Who Experienced Adverse Events (AEs) or Serious AETime frame: Baseline through 84 Months
Locations
408 sites in 38 countries. Site status is shown where the registry gives one.
Arizona Arthritis & Rheumatology Research, PLLC
Glendale, Arizona
Arizona Arthritis & Rheumatology Associates, P. C.
Mesa, Arizona
Sun Valley Arthritis Center, LTD
Peoria, Arizona
Arizona Research Center
Phoenix, Arizona
University of Arizona
Tucson, Arizona
Valley Endocrine, Fresno
Fresno, California
Allergy and Rheumatology Medical Clinic Inc
La Jolla, California
Desert Medical Advances
Palm Desert, California
Stanford University Hospital
Palo Alto, California
Pacific Arthritis Center
Santa Maria, California
Inland Rheumatology & Osteoporosis Medical Group
Upland, California
Boulder Medical Center
Boulder, Colorado
Denver Arthritis Clinic - Lowry
Denver, Colorado
New England Research Associates
Bridgeport, Connecticut
Clinical Research Center of CT/NY
Danbury, Connecticut
Delaware Arthritis
Lewes, Delaware
Orthopedic Research Institute
Boynton Beach, Florida
Medallion Clinical Research Institute
Naples, Florida
Sun Coast Clinical Research, Inc
New Port Richey, Florida
Omega Research Consultants
Orlando, Florida
Rheumatology Associates of Central Florida
Orlando, Florida
Arthritis Research of Florida
Palm Harbor, Florida
West Broward Rheumatology Associates, Inc
Tamarac, Florida
AdventHealth Medical Group
Tampa, Florida
Tampa Medical Group, P.A.
Tampa, Florida
Intermountain Research Center
Boise, Idaho
Deerbrook Medical Associates
Vernon Hills, Illinois
Indiana University Health
Indianapolis, Indiana
Diagnostic Rheumatology and Research
Indianapolis, Indiana
Goldpoint Clinical Research LLC
Indianapolis, Indiana
Klein and Associates MD, PA
Cumberland, Maryland
West Michigan Rheumatology
Grand Rapids, Michigan
Borgess Rheumatology
Kalamazoo, Michigan
Advanced Rheumatology, PC
Lansing, Michigan
Office: Dr. Fiechtner, Justus
Lansing, Michigan
Arthritis and Osteporosis Treatment and Research Center
Flowood, Mississippi
University of Missouri
Columbia, Missouri
Clayton Medical Research
St Louis, Missouri
Arthritis Consultants, Inc.
St Louis, Missouri
Dr. George Timothy Kelly
Las Vegas, Nevada
Showing 40 of 408 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.